The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Adc Therapeutics SA shares valued at $304,500 were purchased by Redmile Group, LLC on Dec 11 ’24. At $3.04 per share, Redmile Group, LLC acquired 100,000 shares. The insider’s holdings grew to 15,666,731 shares worth approximately $57.5 million following the completion of this transaction.
Also, Redmile Group, LLC purchased 100,000 shares, netting a total of over 304,500 in proceeds. Following the buying of shares at $3.04 each, the insider now holds 13,145,712 shares.
Before that, Redmile Group, LLC had sold 25,352 shares from its account. In a trade valued at $52,479, the 10% Owner traded Adc Therapeutics SA shares for $2.07 each. Upon closing the transaction, the insider’s holdings decreased to 25,352 shares, worth approximately $57.13 million.
As published in their initiating research note from Stephens on November 08, 2024, Adc Therapeutics SA [ADCT] has been an Overweight and the price target has been revised to $6. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in late May. As of March 28, 2024, Guggenheim has initiated its “Buy” rating for ADCT. Earlier on August 10, 2023, JP Morgan upgraded its rating. Their new recommendation was “a Neutral” for ADCT stock which previously was a “an Underweight”.
Analyzing ADCT Stock Performance
On last trading session,, Adc Therapeutics SA [NYSE: ADCT] rose 3.97% to $3.67. The stock’s lowest price that day was $3.29, but it reached a high of $3.88 in the same session. During the last five days, there has been a surge of approximately 6.69%. Over the course of the year, Adc Therapeutics SA shares have jumped approximately 84.42%.
Support And Resistance Levels for Adc Therapeutics SA (ADCT)
RSI (Relative Strength Index) is 73.04 on the 14-day chart, showing overbought technical sentiment.
Is Adc Therapeutics SA subject to short interest?
Stocks of Adc Therapeutics SA saw a sharp steep in short interest on 2025-05-30 dropping by -0.2 million shares to 4.27 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 4.47 million shares. A decline of -4.71% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.56 of the overall float, the days-to-cover ratio (short ratio) decline to 6.56.
Which companies own the most shares of Adc Therapeutics SA (ADCT)?
In terms of Adc Therapeutics SA share price expectations, FactSet research, analysts set an average price target of 8 in the next 12 months, up nearly 126.63% from the previous closing price of $3.53. Analysts anticipate Adc Therapeutics SA stock to reach 13 by 2025, with the lowest price target being 7. In spite of this, 7 analysts ranked Adc Therapeutics SA stock as Buy at the end of 2025. On April 24, 2023, BofA Securities assigned a price target of “an Underperform” to the stock and downgraded coverage with a $2.
